Bank of Nova Scotia’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.87M | Buy |
+22,509
| New | +$2.81M | 0.01% | 681 |
|
|
2025
Q2 | – | Sell |
-9,189
| Closed | -$744K | – | 1126 |
|
|
2025
Q1 | $744K | Sell |
9,189
-29,352
| -76% | -$2.62M | ﹤0.01% | 772 |
|
|
2024
Q4 | $3.47M | Buy |
38,541
+21,623
| +128% | +$2.09M | 0.01% | 593 |
|
|
2024
Q3 | $1.67M | Sell |
16,918
-21,282
| -56% | -$2.09M | ﹤0.01% | 687 |
|
|
2024
Q2 | $3.54M | Buy |
38,200
+2,695
| +8% | +$242K | 0.01% | 526 |
|
|
2024
Q1 | $3.37M | Sell |
35,505
-14,868
| -30% | -$1.38M | 0.01% | 571 |
|
|
2023
Q4 | $4.49M | Sell |
50,373
-53,915
| -52% | -$4M | 0.01% | 520 |
|
|
2023
Q3 | $7.62M | Buy |
104,288
+51,503
| +98% | +$4.11M | 0.02% | 355 |
|
|
2023
Q2 | $4.39M | Buy |
52,785
+820
| +2% | +$68.6K | 0.01% | 387 |
|
|
2023
Q1 | $3.96M | Sell |
51,965
-977,990
| -95% | -$81.1M | 0.01% | 414 |
|
|
2022
Q4 | $85.5M | Buy |
1,029,955
+986,355
| +2,262% | +$79.9M | 0.22% | 83 |
|
|
2022
Q3 | $3.46M | Buy |
43,600
+28,824
| +195% | +$2.43M | 0.01% | 499 |
|
|
2022
Q2 | $1.1M | Sell |
14,776
-25,674
| -63% | -$1.93M | ﹤0.01% | 830 |
|
|
2022
Q1 | $3.64M | Sell |
40,450
-1,709,550
| -98% | -$158M | 0.01% | 667 |
|
|
2021
Q4 | $196M | Buy |
+1,750,000
| New | +$211M | 0.27% | 77 |
|
|
2021
Q1 | – | Sell |
-1,715,002
| Closed | -$241M | – | 1113 |
|
|
2020
Q4 | $241M | Buy |
1,715,002
+1,694,803
| +8,391% | +$217M | 0.51% | 50 |
|
|
2020
Q3 | $2.25M | Buy |
20,199
+17,903
| +780% | +$2.01M | 0.01% | 620 |
|
|
2020
Q2 | $257K | Sell |
2,296
-2,020,599
| -100% | -$199M | ﹤0.01% | 840 |
|
|
2020
Q1 | $157M | Sell |
2,022,895
-3,022,705
| -60% | -$268M | 0.54% | 44 |
|
|
2019
Q4 | $480M | Buy |
5,045,600
+4,774,098
| +1,758% | +$413M | 1.17% | 16 |
|
|
2019
Q3 | $20.7M | Sell |
271,502
-17,551
| -6% | -$1.46M | 0.06% | 251 |
|
|
2019
Q2 | $25.4M | Buy |
289,053
+16,943
| +6% | +$1.45M | 0.11% | 191 |
|
|
2019
Q1 | $24.6M | Sell |
272,110
-70,984
| -21% | -$6.04M | 0.1% | 207 |
|
|
2018
Q4 | $24.6M | Buy |
343,094
+118,415
| +53% | +$9.54M | 0.12% | 165 |
|
|
2018
Q3 | $21.5M | Buy |
224,679
+220,696
| +5,541% | +$21.4M | 0.1% | 191 |
|
|
2018
Q2 | $379K | Sell |
3,983
-9,971
| -71% | -$916K | ﹤0.01% | 784 |
|
|
2018
Q1 | $1.22M | Sell |
13,954
-9,042
| -39% | -$825K | 0.01% | 690 |
|
|
2017
Q4 | $1.95M | Buy |
22,996
+7,874
| +52% | +$660K | 0.01% | 620 |
|
|
2017
Q3 | $1.31M | Sell |
15,122
-9,896
| -40% | -$793K | 0.01% | 694 |
|
|
2017
Q2 | $1.94M | Sell |
25,018
-15,248
| -38% | -$1.08M | 0.01% | 639 |
|
|
2017
Q1 | $2.79M | Buy |
+40,266
| New | +$2.7M | 0.01% | 539 |
|
Other funds holding XBI
Bank of Nova Scotia's XBI Position: Q1 2026 in Review
Bank of Nova Scotia opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q1 2026: 22,509 shares worth $2.87M. The stake represents 0.01% of the portfolio and ranks #681 among its holdings. This is a return to the name: Bank of Nova Scotia previously reported a position in XBI as recently as Q1 2025.
Bank of Nova Scotia first reported a position in XBI in Q1 2017 and has held it in 31 quarters since. The position peaked at $480M in Q4 2019. 814 funds tracked by Wall St. Rank hold XBI as of Q1 2026.
- Bank of Nova Scotia held 22,509 shares of State Street SPDR S&P Biotech ETF worth $2.87M as of Q1 2026.
- State Street SPDR S&P Biotech ETF was a new Bank of Nova Scotia position in Q1 2026.
- State Street SPDR S&P Biotech ETF made up 0.01% of Bank of Nova Scotia's portfolio in Q1 2026, its #681 holding.
- Bank of Nova Scotia first reported a position in State Street SPDR S&P Biotech ETF in Q1 2017 and has held it in 31 quarters since.
- Bank of Nova Scotia's State Street SPDR S&P Biotech ETF position peaked at $480M in Q4 2019.
- 814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.
Based on Bank of Nova Scotia's 13F filing for Q1 2026, filed 14 May 2026.